RxDoctor Payments Data

Robert Toborg, MD

Family Medicine · Winston-Salem, NCNPI 1003813650

Payments from drug & device makers

$1,664in general payments, 2019–2025

Across 65 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$278
  • AstraZeneca$269
  • Lilly USA, LLC$261
  • Dexcom, Inc.$260
  • Abbott$194
  • Organon$75
  • plus $327 from 9 others

What the payments were for

  • Food & beverage$1,664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,664 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$93,633
Medicare patients
295
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$136,982
JardianceEmpagliflozin119$117,065
EliquisApixaban124$99,135
MounjaroTirzepatide62$70,159
RybelsusSemaglutide30$45,662
XareltoRivaroxaban27$36,438
TrulicityDulaglutide29$35,114
LinzessLinaclotide29$27,829
FarxigaDapagliflozin Propanediol31$26,952
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$25,843
Soliqua 100-33Insulin Glargine/Lixisenatide21$24,301
Tresiba Flextouch U-100Insulin Degludec38$17,761
MyrbetriqMirabegron25$14,715
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$14,506
VascepaIcosapent Ethyl17$13,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$278$182,644147 claims
Boehringer IngelheimJardiance, Combivent Respimat$33$123,216132 claims
Lilly USA, LLCMounjaro, Trulicity$261$105,27391 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$33$45,22579 claims
AstraZenecaFarxiga, Symbicort$269$39,08376 claims
AbbVieLinzess, Synthroid$72$32,02389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Winston-Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →